1
|
Alwhaibi A, Alsanea S, Almadi B, Al-Sabhan J, Alosaimi FD. Androgen deprivation therapy and depression in the prostate cancer patients: review of risk and pharmacological management. Aging Male 2022; 25:101-124. [PMID: 35343371 DOI: 10.1080/13685538.2022.2053954] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
Purpose: Despite the effectiveness of androgen deprivation therapy in advanced prostate cancer, serious neuropsychiatric consequences in androgen deprivation therapy (ADT)-treated patients, mainly depression, have been concerning and gained more attention recently. This narrative review aims to shed light on the risk and pharmacological management of ADT-induced depression in PCa patients.Methods: We searched PubMed, Scopus and Google Scholar databases using MESH keywords "Prostate cancer OR prostate neoplasm" AND "Depression" AND "Androgen Deprivation Therapy" AND "antidepressants". Search was limited to English and studies conducted on humans. Studies' titles and abstracts were screened, and further information were obtained from the text, if necessary, to decide whether studies are to be included in this review.Results: Our review revealed 23 studies confirming the occurrence and worsening of depressive symptoms in ADT-treated patients, which frequently require pharmacological interventions; whereas 10 studies indicated otherwise. All studies were prospective, retrospective, cross-sectional or case reports. Based on the incidence of depression provided by the observational studies, the average among ADT-treated patients was 18.23% (range: 2.1-46.9%), while it was 8.42% (range: 1.4-23.3%) in the non-ADT patients. Although several treatments have been used for depression in cancer patients, current knowledge lacks observational and controlled studies as well as clinical guidelines that demonstrate efficacy and safety of antidepressants and guide clinicians to the appropriate treatment in these patients, respectively. On the other side, a few clinical studies have been published regarding the efficacy of selective serotonin reuptake inhibitors, selective serotonin and norepinephrine reuptake inhibitors and/or saftey on other ADT associated adverse effects.Conclusions: Our work supports the recent attention towards mood issues as an adverse effect of ADT, and that greater awareness of this is warranted among clinicians. Clinical studies published regarding the use of antidepressants for other ADT associated adverse effects established the foundation that can be adopted to examine these therapies on ADT-induced depression.
Collapse
Affiliation(s)
- Abdulrahman Alwhaibi
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Sary Alsanea
- Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Bana Almadi
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Jawza Al-Sabhan
- Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
| | - Fahad D Alosaimi
- Department of Psychiatry, College of Medicine, King Saud University, Riyadh, Saudi Arabia
| |
Collapse
|
3
|
Rönningås U, Fransson P, Holm M, Wennman-Larsen A. Prostate-specific antigen (PSA) and distress: - a cross-sectional nationwide survey in men with prostate cancer in Sweden. BMC Urol 2019; 19:66. [PMID: 31299962 PMCID: PMC6626380 DOI: 10.1186/s12894-019-0493-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Accepted: 07/02/2019] [Indexed: 02/01/2023] Open
Abstract
Background The prostate-specific antigen (PSA) -value is often used during the prostate cancer trajectory as a marker of progression or response to treatment. Concerns about PSA-values are often expressed by patients in clinical situations. Today there is a lack of larger studies that have investigated the association between PSA-value and distress. The aim was to investigate the association between PSA-values and distress adjusted for sociodemographic factors, hormonal therapy and quality of life (QoL), among men with prostate cancer. Methods In this cross-sectional survey of 3165 men with prostate cancer, members of the Swedish Prostate Cancer Federation, answered questions about sociodemographic factors, PSA, distress, QoL and treatments. Descriptive statistics, and bivariate and multivariable analyses were performed. The result was presented based on four PSA-value groups: 0–19, 20–99, 100–999, and ≥ 1000 ng/ml. Results Of the men, 53% experienced distress. An association between distress and PSA-values was found where higher PSA-values were associated with higher OR:s for experiencing distress in the different PSA-groups: 0–19 ng/ml (ref 1), 20–99 ng/ml (OR 1.25, 95% CI 1.01–1.55), 100–999 ng/ml (OR 1.47, 95% CI 1.12–1.94), ≥1000 ng/ml (OR 1.77, 95% CI 1.11–2.85). These associations were adjusted for sociodemographic factors and hormonal therapy. In the multivariable analyses, beside PSA-values, higher levels of distress were associated with being without partner or hormonal therapy. When adding QoL in the multivariable analysis, the association between PSA and distress did not remain significant. Conclusion These results indicate that the PSA-values are associated with distress, especially for those with higher values. However, to be able to support these men, continued research is needed to gain more knowledge about the mechanisms behind the association between emotional distress and PSA-values.
Collapse
Affiliation(s)
- Ulrika Rönningås
- Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, 171 77, Stockholm, Sweden. .,Department of Oncology, Sundsvall County Hospital, 851 86, Sundsvall, Sweden. .,Department of Nursing Science, Sophiahemmet University, 114 86, Stockholm, Sweden.
| | - Per Fransson
- Department of Nursing, Umeå University, 901 87, Umeå, Sweden.,Cancercentrum, Norrlands University Hospital, 901 85, Umeå, Sweden
| | - Maja Holm
- Department of Nursing Science, Sophiahemmet University, 114 86, Stockholm, Sweden
| | - Agneta Wennman-Larsen
- Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, 171 77, Stockholm, Sweden.,Department of Nursing Science, Sophiahemmet University, 114 86, Stockholm, Sweden
| |
Collapse
|
8
|
Zhang Z, Yang L, Xie D, Shi H, Li G, Yu D. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: A 15-month prospective, observational study. Psychooncology 2017; 26:2238-2244. [PMID: 28474429 DOI: 10.1002/pon.4453] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Revised: 04/23/2017] [Accepted: 04/29/2017] [Indexed: 01/12/2023]
Abstract
OBJECTIVES To evaluate the association between androgen deprivation therapy (ADT) and depression and to identify the risk factors for depressive symptoms among prostate cancer (PCa) patients who received ADT. METHODS We conducted a prospective, longitudinal, controlled study and assessed 3 groups of older patients: the ADT group (men who were presented with maximum androgen block); the radical prostatectomy (RP) group (PCa control group: men who underwent RP without ADT); and the benign prostatic hyperplasia (BPH) group (men who had BPH). All patients completed the demographic questionnaire at baseline and the Zung Self-Rating Depression Scale (SDS) at pretreatment baseline, 1 month, 6 months, 9 months, 12 months and 15 months. RESULTS A total of 146 patients completed the study during the 15-month follow-up. The Self-Rating Depression Scale scores of the 3 groups showed significant differences at 1 month (P < .001), 6 months (P = .009), 9 months (P < .001), 12 months (P < .001), and 15 months (P < .001). At 9 months, 12% of the men in the ADT group, 4.3% in the RP group, and 2% in the BPH group showed depressive symptoms, and there were no significant differences (P = .095). However, there were significant differences among the 3 groups relative to the incidence of depressive symptoms at 12 and 15 months (P < .001, P = .007, respectively). The analysis of the ADT subgroup indicated that alcohol consumption (odds ratio = 6.868; P = .046; 95% CI, 1.038-45.443) and smoking (odds ratio = 13.661; P = 0.013; 95% CI, 1.722-108.386) increased the risk for developing depressive symptoms. CONCLUSIONS Androgen deprivation therapy use does significantly increase the depressive scores and enhance the incidence of depression among PCa patients who received ADT. Smoking and alcohol consumption are associated with depressive symptoms among PCa patients receiving ADT.
Collapse
Affiliation(s)
- Zhiqiang Zhang
- Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Linlin Yang
- Geriatric Ward, The Third Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Dongdong Xie
- Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Haoqiang Shi
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Guangyuan Li
- Department of Urology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
| | - Dexin Yu
- Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
| |
Collapse
|
11
|
Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. J Clin Oncol 2016; 34:1905-12. [PMID: 27069075 PMCID: PMC4966343 DOI: 10.1200/jco.2015.64.1969] [Citation(s) in RCA: 109] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
PURPOSE Androgen deprivation therapy (ADT) may contribute to depression, yet several studies have not demonstrated a link. We aimed to determine whether receipt of any ADT or longer duration of ADT for prostate cancer (PCa) is associated with an increased risk of depression. METHODS We identified 78,552 men older than age 65 years with stage I to III PCa using the SEER-Medicare-linked database from 1992 to 2006, excluding patients with psychiatric diagnoses within the prior year. Our primary analysis was the association between pharmacologic ADT and the diagnosis of depression or receipt of inpatient or outpatient psychiatric treatment using Cox proportional hazards regression. Drug data for treatment of depression were not available. Our secondary analysis investigated the association between duration of ADT and each end point. RESULTS Overall, 43% of patients (n = 33,882) who received ADT, compared with patients who did not receive ADT, had higher 3-year cumulative incidences of depression (7.1% v 5.2%, respectively), inpatient psychiatric treatment (2.8% v 1.9%, respectively), and outpatient psychiatric treatment (3.4% v 2.5%, respectively; all P < .001). Adjusted Cox analyses demonstrated that patients with ADT had a 23% increased risk of depression (adjusted hazard ratio [AHR], 1.23; 95% CI, 1.15 to 1.31), 29% increased risk of inpatient psychiatric treatment (AHR, 1.29; 95% CI, 1.17 to 1.41), and a nonsignificant 7% increased risk of outpatient psychiatric treatment (AHR, 1.07; 95% CI, 0.97 to 1.17) compared with patients without ADT. The risk of depression increased with duration of ADT, from 12% with ≤ 6 months of treatment, 26% with 7 to 11 months of treatment, to 37% with ≥ 12 months of treatment (P trend < .001). A similar duration effect was seen for inpatient (P trend < .001) and outpatient psychiatric treatment (P trend < .001). CONCLUSION Pharmacologic ADT increased the risk of depression and inpatient psychiatric treatment in this large study of elderly men with localized PCa. This risk increased with longer duration of ADT. The possible psychiatric effects of ADT should be recognized by physicians and discussed with patients before initiating treatment.
Collapse
Affiliation(s)
- Kathryn T Dinh
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY
| | - Gally Reznor
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY
| | - Vinayak Muralidhar
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY
| | - Brandon A Mahal
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY
| | - Michelle D Nezolosky
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY
| | - Toni K Choueiri
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY
| | - Karen E Hoffman
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY
| | - Jim C Hu
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY
| | - Christopher J Sweeney
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY
| | - Quoc-Dien Trinh
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY
| | - Paul L Nguyen
- Kathryn T. Dinh, Vinayak Muralidhar, and Brandon A. Mahal, Harvard Medical School; Gally Reznor, Brandon A. Mahal, Michelle D. Nezolosky, Toni K. Choueiri, Christopher J. Sweeney, and Paul L. Nguyen, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School; Quoc-Dien Trinh, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Karen E. Hoffman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Jim C. Hu, Weill Cornell Medical College, James Buchanan Brady Foundation, New York, NY.
| |
Collapse
|